USFDA Classifies Jubilant HollisterStier Spokane CMO Facility as VAI
Jubilant Pharmova Ltd 路 Others (Uncategorized) 路 12 Sept 2026, 1:12 am
USFDA Classifies Jubilant HollisterStier Spokane CMO Facility as VAI Jubilant Pharmova announced that the USFDA concluded its review of the Establishment Inspection Report for the inspection conducted between 8th Jun'26 and 17th Jun'26 at Jubilant HollisterStier LLC's CMO facility in Spokane, Washington, USA. The regulator classified the sterile injectable and ophthalmic manufacturing site as Voluntary Action Indicated (VAI), successfully concluding the regulatory inspection review without major compliance hurdles.
Original exchange filing (PDF)
More announcements from Jubilant Pharmova Ltd
- Investor Meet Outcome 路 16 Nov 2026
- Press Release 路 14 Nov 2026
- Un-audited Financial Results for the Quarter and Half Year ended September 30, 2026 路 14 Nov 2026
- Outcome of Board Meeting 路 14 Nov 2026
- Jubilant Pharmova Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 14 Nov 2026
- Press Release 路 11 Nov 2026
- Allotment 路 06 Nov 2026
- Allotment of NCD 路 06 Nov 2026
